BC Week In Review | Aug 17, 2015
Clinical News

Anti-LPA antibody: Phase I start

Next month, Lpath plans to begin a double-blind, placebo-controlled Phase Ia trial to evaluate single ascending doses of IV Lpathomab in about 36 patients with neuropathic pain. Lpath Inc. (NASDAQ:LPTN), San Diego, Calif.   Product:...
BioCentury | Sep 8, 2014

Parsing Roche's IPF bet

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question now...
Items per page:
1 - 2 of 2